Waterford firm to create 20 jobs


5 Oct 2009

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

Niche Irish company EirGen Pharma is to create 20 new high-value jobs through a €3.3 million expansion programme with Enterprise Ireland support.

The Waterford-based firm is growing its research and development and manufacturing operations and bringing the total number employed up to 40 over the next two years.

EirGen focuses on the development and supply of highly potent drugs typically used in cancer treatment. Set up in 2005, it provides dedicated specialist facilities for drug development and manufacture, servicing the global international pharmaceutical market.

The company was recently granted its first pan-European licence for an early stage breast cancer treatment which is due to be commercially launched this October.

Announcing the investment, Tánaiste and Minister for Enterprise, Trade and Employment Mary Coughlan TD, said the investment was a significant development for EirGen, which would drive its next phase of export-led growth.

“EirGen is a shining example of the innovative, high-technology life sciences companies that are developing in Ireland and that contribute so much — both at a regional level and to strengthening Ireland’s reputation as a centre of excellence for high value innovative services.”

Patsy Carney, managing director and co-founder of EirGen commented at the announcement: "Our state-of-the art, purpose-built, high containment facility, coupled with our highly experienced team has resulted in eight products under registration with the US Food & Drug Administration (FDA) and the European regulatory authorities and a total of 13 successful clinical studies.”

EirGen plans to build on its success in the US and Europe and expand in new growth markets such as Japan, Latin America, Asia and South Africa, having already secured agreements with a number of pharmaceutical companies in these territories.

Article courtesy of businessandleadership.com